TVS Motor is infiltrating more in Ultraviolette EV
FabiFlu will be the first Favipiravir-approved by DCGI for the treatment of Covid-19, the company said in a statement.
On Friday 19th June 2020, Glenmark a Mumbai based Pharma company received approval from Drugs Controller General of India(DCGI), for manufacturing of antiviral drug for the treatment of patients with mild to moderate COVID-19. The brand today has launched the product Favipiravir under its brand name FabiFlu. “This approval comes at a time when cases in India are spiralling like never before, putting tremendous pressure on our healthcare system,” said Glenn Saldanha, Glenmark Pharmaceuticals Chairman and MD.
“Glenmark will work closely with the government and medical community to make FabiFlu quickly accessible to patients across the country,” Saldanha said. The drug will be available only as a prescription-based medication for Rs.103/tablet, with recommended dose being 1,800 mg 2/day one, followed by 800mg 2/daily up to day14. (Bloomberg)
Thanks for sharing useful information ๐
ReplyDelete